Generic Name and Formulations:
Rimexolone 1%; oph susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for VEXOL:
Post-op inflammation. Anterior uveitis.
Post-op: 1–2 drops into conjunctival sac(s) 4 times daily; start 24 hrs after surgery and continue through 1st 2 weeks post-op. Uveitis: 1–2 drops into the conjunctival sac(s) every hour while awake for 1st week, then 1 drop every 2 hrs while awake for 2nd week, then taper until resolved.
Epithelial herpes simplex keratitis and other viral infections including vaccinia, varicella. Ocular mycobacterial, fungal, or untreated purulent infections.
Corneal or scleral thinning. Monitor intraocular pressure. Pregnancy (Cat.C). Nursing mothers: not recommended.
Blurred vision, discharge, discomfort, ocular pain, increased intraocular pressure, foreign body sensation, hyperemia, pruritus; may mask secondary ocular infections; ocular hypertension/glaucoma, optic nerve damage, defects in visual acuity and visual fields, posterior subcapsular cataract formation, superinfection possible with prolonged use.
Clinical Pain Advisor Articles
- Opioids: Clinician Concern and Prescribing Practices
- Quantity of Opioids Prescribed Linked to Higher Patient-Reported Consumption
- Ensuring Safety During Long-Term Opioid Therapy
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Drug Overdose Mortality Rates Rising in the United States
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- Tips Provided for Budgeting in Medical Residency
- Give Thanks: The Role of Gratitude in Combating Burnout
- Persistent Back Pain Linked to Earlier Mortality in Older Women
- Cannabinoids May Be Effective on Experimental Pain Threshold and Tolerance, Not Intensity
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain